| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Medtronic plc (NYSE:MDT) will release earnings results for the second quarter, before the opening bell on Tuesday, Nov. 18.
Analysts expect the Galway, Ireland-based company to report quarterly earnings of $1.31 per share, up from $1.26 per share in the year-ago period. The consensus estimate for Medtronic's quarterly revenue is $8.86 billion. Benzinga Pro data shows $8.4 billion in quarterly revenue a year ago.
On Oct. 8, Medtronic announced the commencement of the Embrace Gynecology investigational device exemption (IDE) U.S. clinical study to assess the safety and effectiveness of its Hugo robotic-assisted surgery (RAS) system in gynecological procedures.
Shares of Medtronic rose 0.4% to close at $96.28 on Monday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.
Considering buying MDT stock? Here’s what analysts think:

Photo via Shutterstock
Posted In: MDT